Form D · Pharmaceuticals
ASPEN PARK PHARMACEUTICALS, INC.
New York, NY · CIK 0001620965
Offering snapshot reported Mar 31, 2016 · SEC filing
- Reported sold
- $1.25M Offering amount: $2M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 30, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 31, 2016 | Initial | $1,250,000 | No comparison | 9 | SEC filing |
| Oct 10, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-260428
Source: Form D, filed Mar 31, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Harry Fisch, Md | Director, Executive |
| Harry Fisch, M.D. | Director, Executive |
| Mitchell S. Steiner | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
944 Park Avenue
New York, NY, 10028
New York, NY, 10028